Imexpharm Statistics
Total Valuation
Imexpharm has a market cap or net worth of VND 8.04 trillion. The enterprise value is 7.97 trillion.
Market Cap | 8.04T |
Enterprise Value | 7.97T |
Important Dates
The next estimated earnings date is Friday, July 18, 2025.
Earnings Date | Jul 18, 2025 |
Ex-Dividend Date | Jun 9, 2025 |
Share Statistics
Imexpharm has 154.01 million shares outstanding. The number of shares has decreased by -1.93% in one year.
Current Share Class | 154.01M |
Shares Outstanding | 154.01M |
Shares Change (YoY) | -1.93% |
Shares Change (QoQ) | -7.30% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | 0.26% |
Float | n/a |
Valuation Ratios
The trailing PE ratio is 26.00.
PE Ratio | 26.00 |
Forward PE | n/a |
PS Ratio | 3.48 |
PB Ratio | 3.58 |
P/TBV Ratio | 3.70 |
P/FCF Ratio | n/a |
P/OCF Ratio | 80.05 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.86, with an EV/FCF ratio of -5,618.24.
EV / Earnings | 25.79 |
EV / Sales | 3.45 |
EV / EBITDA | 14.86 |
EV / EBIT | 18.43 |
EV / FCF | -5,618.24 |
Financial Position
The company has a current ratio of 4.48, with a Debt / Equity ratio of 0.17.
Current Ratio | 4.48 |
Quick Ratio | 2.11 |
Debt / Equity | 0.17 |
Debt / EBITDA | 0.73 |
Debt / FCF | -274.10 |
Interest Coverage | 81.35 |
Financial Efficiency
Return on equity (ROE) is 15.18% and return on invested capital (ROIC) is 11.03%.
Return on Equity (ROE) | 15.18% |
Return on Assets (ROA) | 10.04% |
Return on Invested Capital (ROIC) | 11.03% |
Return on Capital Employed (ROCE) | 17.27% |
Revenue Per Employee | 1.60B |
Profits Per Employee | 213.81M |
Employee Count | 1,452 |
Asset Turnover | 0.86 |
Inventory Turnover | 1.78 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +67.25% in the last 52 weeks. The beta is 0.75, so Imexpharm's price volatility has been lower than the market average.
Beta (5Y) | 0.75 |
52-Week Price Change | +67.25% |
50-Day Moving Average | 46,557.00 |
200-Day Moving Average | 46,446.75 |
Relative Strength Index (RSI) | 60.45 |
Average Volume (20 Days) | 314,976 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Imexpharm had revenue of VND 2.31 trillion and earned 309.16 billion in profits. Earnings per share was 2,007.45.
Revenue | 2.31T |
Gross Profit | 1.09T |
Operating Income | 432.60B |
Pretax Income | 421.71B |
Net Income | 309.16B |
EBITDA | 536.47B |
EBIT | 432.60B |
Earnings Per Share (EPS) | 2,007.45 |
Balance Sheet
The company has 455.35 billion in cash and 388.98 billion in debt, giving a net cash position of 66.38 billion or 430.98 per share.
Cash & Cash Equivalents | 455.35B |
Total Debt | 388.98B |
Net Cash | 66.38B |
Net Cash Per Share | 430.98 |
Equity (Book Value) | 2.25T |
Book Value Per Share | 14,593.83 |
Working Capital | 1.43T |
Cash Flow
In the last 12 months, operating cash flow was 100.43 billion and capital expenditures -101.85 billion, giving a free cash flow of -1.42 billion.
Operating Cash Flow | 100.43B |
Capital Expenditures | -101.85B |
Free Cash Flow | -1.42B |
FCF Per Share | -9.21 |
Margins
Gross margin is 47.25%, with operating and profit margins of 18.74% and 14.45%.
Gross Margin | 47.25% |
Operating Margin | 18.74% |
Pretax Margin | 18.27% |
Profit Margin | 14.45% |
EBITDA Margin | 23.24% |
EBIT Margin | 18.74% |
FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 0.96%.
Dividend Per Share | 500.00 |
Dividend Yield | 0.96% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | 1 |
Payout Ratio | 21.00% |
Buyback Yield | 1.93% |
Shareholder Yield | 2.89% |
Earnings Yield | 3.85% |
FCF Yield | -0.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | |
Lynch Upside | |
Graham Number | |
Graham Upside |
Stock Splits
The last stock split was on September 17, 2024. It was a forward split with a ratio of 2.
Last Split Date | Sep 17, 2024 |
Split Type | Forward |
Split Ratio | 2 |
Scores
Imexpharm has an Altman Z-Score of 7.91.
Altman Z-Score | 7.91 |
Piotroski F-Score | n/a |